BRCA1 and triple-negative breast carcinoma: In triple-negative breast cancers, ATR inhibitors are highly efficient in patient-derived xenografts that have a BRCA1 mutation or that exhibit the BRCA-like phenocopy when combined with irinotecan, a clinically approved topoisomerase 1 inhibitor that causes double-stranded breaks [101].